Executive Director, HTE and Lead Discovery Capabilities, Merck Sharp & Dohme
Global Engage is pleased to announce as part of their Drug Discovery Series of events, The Medicinal Chemistry Summit: USA which will be held on September 17th – 18th 2018 in Boston, USA. This event will be the sister meeting to their successful European Medicinal Chemistry Summit of 2017.
Designed to attract experts working in all areas of medicinal chemistry, the Summit has three tracks focusing on key topics such as hit-to-lead optimization, target validation, the implementation of artificial intelligence into the drug discovery process, small molecule immuno-oncology, small molecule targeting of RNA, ADCs and SBDD. In addition, this conference will have an entire day focused on the enabling technologies revolutionizing medicinal chemistry – protein degradation and DNA encoded libraries. The Summit will provide a forum to network, learn, and engage with senior representatives of leading pharmaceutical and biotech companies worldwide.
Vice President, Discovery Chemistry & Technologies, & Distinguished Research Fellow, AbbVie
Senior Research Scientist, Early CVRM Medicinal Chemistry, R&D Biopharmaceuticals, AstraZeneca
This comprehensive two-day summit, featuring over 35 presentations will provide experts with an exceptional environment in which to debate the key issues facing them today. These include: optimizing hit to lead quality and timescale, protein degradation, DNA encoded libraries, small molecule immuno-oncology research, SBDD, and the use of AI in the drug discovery process.
An extended panel discussion will explore the future of medicinal chemistry, while 7 roundtable discussions, led by experts, will enable a deeper investigation of subjects including DNA encoded libraries, artificial intelligence in medicinal chemistry and predictive toxicology – improving compound safety.